Hyperosmolar hyperglycemic state is a life-threatening emergency manifested by marked elevation of blood glucose and hyperosmolarity with little or no ketosis. Although there are multiple precipitating causes, underlying infections are the most common. Other causes include certain medications, nonadherence to therapy, undiagnosed diabetes mellitus, substance abuse, and coexisting disease. In children and adolescents, hyperosmolar hyperglycemic state is often present when type 2 diabetes is diagnosed. Physical findings include profound dehydration and neurologic symptoms ranging from lethargy to coma. Treatment begins with intensive monitoring of the patient and laboratory values, especially glucose, sodium, and potassium levels. Vigorous correction of dehydration is critical, requiring an average of 9 L of 0.9% saline over 48 hours in adults. After urine output is established, potassium replacement should begin. Once dehydration is partially corrected, adults should receive an initial bolus of 0.1 units of intravenous insulin per kg of body weight, followed by a continuous infusion of 0.1 units per kg per hour (or a continuous infusion of 0.14 units per kg per hour without an initial bolus) until the blood glucose level decreases below 300 mg per dL. In children and adolescents, dehydration should be corrected at a rate of no more than 3 mOsm per hour to avoid cerebral edema. Identification and treatment of underlying and precipitating causes are necessary.
Download full-text PDF |
Source |
---|
J Med Toxicol
December 2024
Division of Pediatric Emergency Medicine, Johns Hopkins Children's Center, 1800 Orleans Street, Baltimore, MD, 21287, USA.
Introduction: Diazoxide is the first-line treatment for children with hyperinsulinemic hypoglycemia (HI). In these cases, diazoxide raises blood glucose levels by suppressing insulin release, preventing hypoglycemia, and potentially devastating end-organ sequelae. Hyperosmolar hyperglycemic state (HHS) is an exceedingly rare side effect of diazoxide.
View Article and Find Full Text PDFAm J Emerg Med
December 2024
Department of Emergency Medicine, Sharp Grossmont Hospital, La Mesa, CA, United States.
Capivasertib is a new targeted therapy for the treatment of select cases of hormone receptor positive, HER2 negative advanced breast cancer. Hyperglycemia is a known adverse effect of capivasertib with a 16 % incidence rate, however life-threatening hyperglycemia occurs rarely (incidence 0.3 %).
View Article and Find Full Text PDFJ Clin Endocrinol Metab
December 2024
Division of Pediatric Endocrinology, Department of Pediatrics, UT Southwestern Medical Center, Dallas TX.
Background: Adverse Outcomes (death or ICU stays longer than 48h) in children with diabetic ketoacidosis (DKA) or hyperglycemic-hyperosmolar syndrome (HHS) can be predicted by a composite risk score based on severity of hyperglycemia and acidosis, and presence of type 2 diabetes. Because most high-risk patients nevertheless do not experience an Adverse Outcome, we tried to identify differences in management or other clinical characteristics that influenced outcomes.
Methods: In a previously defined group of 4565 admissions for DKA-HHS in 2010-2023, 109 had Adverse Outcomes.
Clin Case Rep
November 2024
Division of Nephrology, Department of Medicine, College of Medicine King Saud University Riyadh Saudi Arabia.
Hyperosmolar hyperglycemic syndrome (HHS) is a common complication of diabetes mellitus. The episodes of HHS have been reported in patients with no prior history of diabetes. However, these incidents have rarely been reported in the literature.
View Article and Find Full Text PDFIntern Med
November 2024
Department of Gastroenterology and Hepatology, Osaka Rosai Hospital, Japan.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!